ApoB: the cholesterol number that beats LDL.

Apolipoprotein B, ApoB, is the structural protein wrapped around every cholesterol particle capable of burrowing into an artery wall, and because each particle carries exactly one ApoB molecule, measuring it gives you a direct count of how many of those particles are circulating in your blood. That distinction matters more than it sounds. LDL cholesterol tells you how much cholesterol your particles are carrying. ApoB tells you how many particles there are. Atherosclerosis is caused by particles crossing into the artery wall, not by the cargo they happen to hold, which is why, in head-to-head comparisons, ApoB predicts heart attacks better than the number most Australians actually get told.

The key facts, up front

• ApoB is the strongest of the three routine lipid risk markers. Across 233,455 people and 22,950 cardiovascular events, ApoB outperformed both non-HDL cholesterol and LDL cholesterol as a predictor of risk.
• When you analyse them together, LDL cholesterol and triglycerides stop mattering. In UK Biobank, only ApoB remained independently associated with myocardial infarction once particle count was accounted for.
• Roughly 1 in 5 people are discordant, normal LDL cholesterol, elevated ApoB, and a risk profile their standard blood test never showed them.
• It is causal, not just correlated. Mendelian randomisation across more than two million participants shows the risk of heart disease tracks lifetime particle exposure.
• It is not on your standard GP panel. In Australia, a routine lipid screen reports total cholesterol, LDL, HDL and triglycerides. ApoB has to be asked for.

Why particle count beats cholesterol mass

Picture arterial plaque forming the way it actually does: individual lipoprotein particles collide with the endothelial lining, a fraction of them cross into the artery wall, and those that get trapped there trigger the inflammatory cascade that builds plaque over decades. The probability of that happening depends on how many particles hit the wall, not how full each one is.

Two people can have an identical LDL cholesterol of 3.0 mmol/L. One carries a modest number of large, cholesterol-rich particles. The other carries a much larger number of small, cholesterol-depleted ones. Same number on the report; materially different rate of collisions with the artery wall. ApoB separates them; LDL cholesterol cannot.

This is also why ApoB captures risk that a cholesterol number misses entirely. It counts LDL, VLDL, IDL and Lp(a), every atherogenic class, in a single measurement.

What the clinical evidence actually shows

ApoB has one of the most consistent evidence bases of any biomarker in The HodieLabs Evidence-Based Clinical Library, spanning epidemiology, genetics and randomised trials that all point the same direction.

• Sniderman meta-analysis (Circulation: Cardiovascular Quality and Outcomes, 2011): twelve independent cohorts, 233,455 subjects, 22,950 events. In head-to-head comparison, ApoB was the most potent marker of cardiovascular risk (relative risk ratio 1.43 per standard deviation), LDL cholesterol the weakest (1.25), with non-HDL cholesterol in between (1.34).
• UK Biobank, FOURIER and IMPROVE-IT (Marston et al. JAMA Cardiology 2022): in the primary prevention cohort, ApoB, non-HDL cholesterol and triglycerides were each individually associated with heart attack, but when modelled together, only ApoB remained significant (adjusted hazard ratio 1.27 per standard deviation). The authors' conclusion was blunt: the number of ApoB-containing particles is what drives risk, not the cholesterol or triglyceride content they carry.
• CARDIA study (Wilkins et al. Journal of the American College of Cardiology 2016): young adults whose ApoB was high despite a reassuring LDL cholesterol went on to develop significantly more coronary artery calcification. Discordance is not a statistical curiosity. It shows up in the arteries decades later.
• European Atherosclerosis Society consensus (Ference et al. European Heart Journal 2017): synthesising more than 200 prospective cohorts, Mendelian randomisation studies and randomised trials, over two million participants and 150,000 cardiovascular events, the panel concluded that LDL particles cause atherosclerotic cardiovascular disease, and that risk reduction is proportional to the absolute fall in particle number multiplied by the duration of exposure.
• Cholesterol Treatment Trialists' Collaboration (The Lancet, 2010): 26 randomised trials, 170,000 participants. Each 1 mmol/L reduction in LDL cholesterol reduced major vascular events by approximately 22% per year, the interventional bookend to the genetic evidence.

Where the evidence is more nuanced, it is worth saying so. ApoB and LDL cholesterol agree most of the time, and for the majority of people with a clean metabolic profile the two markers will lead to the same clinical decision. ApoB's advantage is concentrated in the group where they disagree, and there is no way to know which group you are in without measuring it. It is also true that no randomised trial has yet compared "treat to an ApoB target" against "treat to an LDL-C target" and measured hard outcomes. The case for ApoB rests on the consistency of observational, genetic and mechanistic evidence rather than a single definitive trial.

Discordance: the one-in-five problem

Discordance is when your LDL cholesterol and your ApoB tell different stories. It is common, affecting roughly one in five people tested, and it is not random. It clusters in exactly the people whose risk is most often underestimated: those with elevated triglycerides, insulin resistance, type 2 diabetes, central obesity or metabolic syndrome. In those states the liver produces more particles, each carrying less cholesterol. The lipid panel looks acceptable. The particle count does not.

This is why the 2019 ESC/EAS dyslipidaemia guidelines specifically recommend ApoB measurement for people with high triglycerides, diabetes, obesity, metabolic syndrome or very low LDL cholesterol. The precise situations where a cholesterol mass measurement is least reliable.

How HodieLabs interprets your ApoB result

Every biomarker in the HodieLabs Evidence-Based Clinical Library is interpreted against published clinical authority standards, never arbitrary "optimal" ranges. For ApoB, measured in g/L, the bands follow the 2019 ESC/EAS dyslipidaemia guidelines:

• Below 0.80 g/L, optimal. The primary-prevention target for moderate-risk adults.
• 0.80–1.00 g/L, borderline. Acceptable at low absolute risk; a target for action if other risk factors are present.
• 1.01–1.30 g/L, high. Particle burden is meaningfully elevated and warrants an intervention plan.
• Above 1.30 g/L, very high. Aggressive management indicated, with specialist input where appropriate.

Risk-stratified guideline goals sit tighter still: the ESC/EAS set secondary ApoB targets of under 1.00 g/L for moderate risk, under 0.80 g/L for high risk and under 0.65 g/L for very high risk. Interpretation is never done on ApoB alone. It is read alongside Lp(a), hs-CRP, the metabolic panel and your absolute cardiovascular risk, because the same ApoB carries very different consequences in a 35-year-old non-smoker and a 60-year-old with hypertension.

The Australian gap

Cardiovascular disease remains involved in roughly one in four Australian deaths, and the 2023 Australian guideline for assessing and managing cardiovascular disease risk built its national risk calculator around total and HDL cholesterol, the markers most reliably available in general practice. That is a defensible population-health choice, but it means ApoB sits outside routine Australian risk assessment altogether. Standard GP lipid panels don't include it, and most people have never been offered it.

The practical consequence: a large number of Australians have been told their cholesterol is "fine" on the basis of the weakest of the three available markers, while the strongest one has never been measured.

How testing works at HodieLabs

ApoB is measured in every Health Blueprint at our Melbourne Preventative Health & Longevity Clinic, alongside Lp(a), hs-CRP and the full cardiovascular and metabolic panel, and interpreted by a doctor against the guideline thresholds above, in the context of your complete biomarker picture. It does not require fasting, it is tracked annually, and where the number is elevated your plan targets the modifiable drivers first, with advanced imaging such as CT calcium scoring where clinically indicated.

The bottom line

If you are going to measure one lipid number, the evidence says measure the one that counts particles. ApoB is inexpensive, standardised, doesn't require fasting, and in the roughly one in five people whose cholesterol and particle count disagree, it is the difference between a false reassurance and an accurate picture of lifetime risk.

References

1. Sniderman AD, Williams K, Contois JH, et al. A meta-analysis of low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B as markers of cardiovascular risk. Circ Cardiovasc Qual Outcomes. 2011;4(3):337–345.
2. Marston NA, Giugliano RP, Melloni GEM, et al. Association of apolipoprotein B-containing lipoproteins and risk of myocardial infarction in individuals with and without atherosclerosis: distinguishing between particle concentration, type, and content. JAMA Cardiol. 2022;7(3):250–256.
3. Ference BA, Ginsberg HN, Graham I, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2017;38(32):2459–2472.
4. Wilkins JT, Li RC, Sniderman A, Chan C, Lloyd-Jones DM. Discordance between apolipoprotein B and LDL-cholesterol in young adults predicts coronary artery calcification: the CARDIA study. J Am Coll Cardiol. 2016;67(2):193–201.
5. Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41(1):111–188.
6. Cholesterol Treatment Trialists' Collaboration (Baigent C, et al.). Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376(9753):1670–1681.
7. Richardson TG, Sanderson E, Palmer TM, et al. Evaluating the relationship between circulating lipoprotein lipids and apolipoproteins with risk of coronary heart disease: a multivariable Mendelian randomisation analysis. PLoS Med. 2020;17(3):e1003062.
8. Commonwealth of Australia. 2023 Australian guideline for assessing and managing cardiovascular disease risk. Med J Aust. 2024;220(9):482–490.

This article is general information, not medical advice. Speak with your GP about what testing and care is appropriate for you.